Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer

Blaes, Franz; Klotz, Markus; Huwer, Hanno; Straub, U; Kalweit, G; Schimrigk, К.; Schäfers, Hans‐Joachim

doi:10.1016/s0003-4975(99)01198-4

Cited by 56 publications

(37 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22,23 Autoantibodies correlated with prolonged survival of tumor patients are rare and to the best of our knowledge of low specificity. Specifically, correlations with prolonged survival of tumor patients are shown for antinuclear autoantibodies in patients with nonsmall-cell lung cancer 24 and for anti dsDNA antibodies in patients with colorectal adenocarcinoma. 25 As for glioblastoma, circulating immune complexes of IgG that are bound to various antigens in patient sera were correlated with poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

Autoantibodies against GLEA2 and PHF3 in glioblastoma: Tumor‐associated autoantibodies correlated with prolonged survival

Pallasch

Struss

Munnia

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Using serological identification of recombinantly expressed tumor antigens (SEREX), we identified several autoantibodies against glioma‐expressed antigens including GLEA1, GLEA2 and PHD‐finger protein3 (PHF3). Analysing sera of 62 glioblastoma patients, we found an antibody response against GLEA1 in 15 sera (24.2%), against GLEA2 in 30 sera (48.4%) and against PHF3 in 35 sera (56.5%). Relating patient survival to the occurrence of autoantibodies against either GLEA1, GLEA2 or PHF3, we found a significant prolonged survival for glioblastoma patients positive for autoantibodies against GLEA2 (p = 0.0115) and PHF3 (p = 0.0031), respectively. The median survival of patients with GLEA2 antibodies was increased to 17.4 months and for patients with PHF3 antibodies to 14.7 months, as compared to 7.2 months for patients without GLEA2 or PHF3 antibodies. There was no significant correlation between patient survival and GLEA1‐autoantibodies (p = 0.1611). Herein we present autoantibodies that are: (i) most frequent in glioblastoma patients; (ii) specific for glioblastoma‐associated antigens; and (iii) significantly correlated with prolonged survival in patients with glioblastoma. © 2005 Wiley‐Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Autoantibodies against GLEA2 and PHF3 in glioblastoma: Tumor‐associated autoantibodies correlated with prolonged survival

Pallasch

Struss

Munnia

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…It is known that detection of antinuclear antibodies in non-small cell lung cancer correlates with longer survival (Blaes et al, 2000) and that p53 antibodies in tumours of the breast, colon and stomach are correlated with poor prognosis (Soussi, 2000). Obviously, there is an in¯uence of the antibody response on the tumour development in these cases.…”

Section: Discussionmentioning

confidence: 99%

PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme

et al. 2001

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM), a malignant astrocytic tumour, represents the most frequent tumour of the human brain. Nevertheless, its molecular pathology is not well understood. We utilized the immune system, which contributes to cancer protection, to help identify new GBM-related genes. By screening a human GBM cDNA library with autologous patient serum (SEREX-approach), we isolated a gene termed PHF3 (PHD finger protein 3). The gene product of PHF3 is immunogenic in GBM as tested in an allogenic patient serum screening demonstrating antibodies in 24 of 39 (61.53%) sera, whereas none of the 14 healthy persons had antibodies against PHF3. While previous SEREX studies revealed allogenic antibody responses up to 40%, our results for PHF3 represent the highest reported rate for a speci®c antibody response. We show that GBM patients with an antibody response against PHF3 show signi®cant better survival than patients without PHF3-speci®c antibodies. Because the amino acid sequence of PHF3 contains a PHD ®nger (also termed LAP motif), a TFIIS homology, a proline rich region and nuclear localization signals, it supposedly functions as a transcription factor. A polyclonal antibody generated against PHF3 shows nuclear expression in most investigated formalin-®xed, paran embedded tissues. In GBM, PHF3 expression is concentrated in cells surrounding necroses. Oncogene (2001) 20, 4107 ± 4114.

show abstract

“…It is, however, reported that some cancer and even AIDS patients are also characterized by the increase in production of anti-dsDNA autoantibodies [3][4][5][6][7]. Although our understanding of autoimmune diseases remains confused, origins of anti-dsDNA autoantibodies and their pathological role have been widely investigated.…”

Section: Introductionmentioning

confidence: 99%

Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice

Zhang

et al. 2005

Immunology Letters

View full text Add to dashboard Cite

Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer

Cited by 56 publications

References 19 publications

Autoantibodies against GLEA2 and PHF3 in glioblastoma: Tumor‐associated autoantibodies correlated with prolonged survival

Autoantibodies against GLEA2 and PHF3 in glioblastoma: Tumor‐associated autoantibodies correlated with prolonged survival

PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme

Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice

Contact Info

Product

Resources

About